These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8800795)

  • 1. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses.
    Jahrling PB; Geisbert J; Swearengen JR; Jaax GP; Lewis T; Huggins JW; Schmidt JJ; LeDuc JW; Peters CJ
    Arch Virol Suppl; 1996; 11():135-40. PubMed ID: 8800795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.
    Jahrling PB; Geisbert TW; Geisbert JB; Swearengen JR; Bray M; Jaax NK; Huggins JW; LeDuc JW; Peters CJ
    J Infect Dis; 1999 Feb; 179 Suppl 1():S224-34. PubMed ID: 9988188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.
    Pyankov OV; Setoh YX; Bodnev SA; Edmonds JH; Pyankova OG; Pyankov SA; Pali G; Belford S; Lu L; La M; Lovrecz G; Volchkova VA; Chappell KJ; Watterson D; Marsh G; Young PR; Agafonov AA; Farmer JF; Volchkov VE; Suhrbier A; Khromykh AA
    Sci Rep; 2017 Feb; 7():41537. PubMed ID: 28155869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
    Parren PW; Geisbert TW; Maruyama T; Jahrling PB; Burton DR
    J Virol; 2002 Jun; 76(12):6408-12. PubMed ID: 12021376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.
    Wang H; Wong G; Zhu W; He S; Zhao Y; Yan F; Rahim MN; Bi Y; Zhang Z; Cheng K; Jin H; Cao Z; Zheng X; Gai W; Bai J; Chen W; Zou Y; Gao Y; Gao GF; Yang S; Xia X; Qiu X
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2.
    Racine T; Denizot M; Pannetier D; Nguyen L; Pasquier A; Raoul H; Saluzzo JF; Kobinger G; Veas F; Herbreteau CH
    J Infect Dis; 2019 Jun; 220(1):41-45. PubMed ID: 30852585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.
    Regules JA; Beigel JH; Paolino KM; Voell J; Castellano AR; Hu Z; Muñoz P; Moon JE; Ruck RC; Bennett JW; Twomey PS; Gutiérrez RL; Remich SA; Hack HR; Wisniewski ML; Josleyn MD; Kwilas SA; Van Deusen N; Mbaya OT; Zhou Y; Stanley DA; Jing W; Smith KS; Shi M; Ledgerwood JE; Graham BS; Sullivan NJ; Jagodzinski LL; Peel SA; Alimonti JB; Hooper JW; Silvera PM; Martin BK; Monath TP; Ramsey WJ; Link CJ; Lane HC; Michael NL; Davey RT; Thomas SJ;
    N Engl J Med; 2017 Jan; 376(4):330-341. PubMed ID: 25830322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.
    Dye JM; Wu H; Hooper JW; Khurana S; Kuehne AI; Coyle EM; Ortiz RA; Fuentes S; Herbert AS; Golding H; Bakken RA; Brannan JM; Kwilas SA; Sullivan EJ; Luke TC; Smith G; Glenn G; Li W; Ye L; Yang C; Compans RW; Tripp RA; Jiao JA
    Sci Rep; 2016 Apr; 6():24897. PubMed ID: 27109916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
    Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE
    J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells.
    Rao M; Bray M; Alving CR; Jahrling P; Matyas GR
    J Virol; 2002 Sep; 76(18):9176-85. PubMed ID: 12186901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.
    Kudoyarova-Zubavichene NM; Sergeyev NN; Chepurnov AA; Netesov SV
    J Infect Dis; 1999 Feb; 179 Suppl 1():S218-23. PubMed ID: 9988187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.
    Mire CE; Geisbert JB; Agans KN; Thi EP; Lee AC; Fenton KA; Geisbert TW
    J Infect Dis; 2016 Oct; 214(suppl 3):S367-S374. PubMed ID: 27571900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic.
    Jahrling PB; Geisbert TW; Jaax NK; Hanes MA; Ksiazek TG; Peters CJ
    Arch Virol Suppl; 1996; 11():115-34. PubMed ID: 8800793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 16. [Developing methods of specific heterologic immunoglobulins preparation for urgent prevention of Ebola fever and study of their properties].
    Cherpunov AA; Kudoiarova-Zubavichene NM; Dedkova LM; Sergeev NN; Netesov SV
    Vestn Ross Akad Med Nauk; 1998; (4):24-9. PubMed ID: 9633237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.
    Wong G; Richardson JS; Pillet S; Racine T; Patel A; Soule G; Ennis J; Turner J; Qiu X; Kobinger GP
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S379-83. PubMed ID: 25957963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELISA for the detection of antibodies to Ebola viruses.
    Ksiazek TG; West CP; Rollin PE; Jahrling PB; Peters CJ
    J Infect Dis; 1999 Feb; 179 Suppl 1():S192-8. PubMed ID: 9988184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever.
    Borisevich IV; Chemikova NK; Markov VI; Krasnianskiy VP; Borisevich SV; Rozhdestvenskiy EV
    Vopr Virusol; 2017; 62(1):25-9. PubMed ID: 29323843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
    Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
    J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.